Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;43(40):2971-2985.
doi: 10.1038/s41388-024-03139-5. Epub 2024 Aug 28.

m6A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis

Affiliations

m6A modification of lipoyltransferase 1 inhibits bladder cancer progression by activating cuproptosis

Kaixuan Du et al. Oncogene. 2024 Sep.

Abstract

Cuproptosis, a cell death process caused by copper ions, is mediated by protein lipidation related to lipoic acid metabolism. There is a close connection between cuproptosis and the progression and prognosis of various tumors. Here, we identified lipoyltransferase 1 (LIPT1), a key gene related to cuproptosis, was downregulated in bladder cancer (BLCA) and was associated with unfavorable patient prognosis. Restoring the LIPT1 expression in BLCA cells suppressed the proliferation and promoted cuproptosis. Moreover, the consequences of RNA sequencing and Bodipy staining showed that the metabolic pathway mediated by LIPT1 inhibited the accumulation of lipid droplets in cells, disrupted endoplasmic reticulum (ER) homeostasis, and promoted cell apoptosis. Additionally, overexpression of LIPT1 not only repressed the proliferation rate of BLCA cells in vitro but also in vivo. Mechanistically, YTH N6-Methyladenosine RNA Binding Protein F2 (YTHDF2) promoted the degradation of LIPT1 mRNA in a m6A-dependent manner. In summary, these conclusions reveal that LIPT1 promotes cuprotosis and ER stress to inhibit the progression of BLCA, indicating that LIPT1 will provide a powerful treatment direction and drug target for treating BLCA.

PubMed Disclaimer

References

    1. Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38:1895–904. https://doi.org/10.1007/s00345-019-02984-4 . - DOI - PubMed
    1. Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet (Lond, Engl). 2022;400:1712–21. https://doi.org/10.1016/s0140-6736(22)01188-6 . - DOI
    1. Grayson M. Bladder cancer. Nature. 2017;551:S33. https://doi.org/10.1038/551S33a . - DOI - PubMed
    1. Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022;7:378. https://doi.org/10.1038/s41392-022-01229-y . - DOI - PubMed - PMC
    1. Fukai T, Ushio-Fukai M, Kaplan JH. Copper transporters and copper chaperones: roles in cardiovascular physiology and disease. Am J Physiol Cell Physiol. 2018;315:C186–c201. https://doi.org/10.1152/ajpcell.00132.2018 . - DOI - PubMed - PMC

LinkOut - more resources